- Home
- DCOM vs VRDN Comparison
DCOM vs VRDN Comparison
Compare DCOM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCOM | VRDN |
|---|---|---|
| Founded | 1864 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DCOM | VRDN |
|---|---|---|
| Price | $40.41 | $24.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $37.80 | $35.46 |
| AVG Volume (30 Days) | 307.0K | ★ 1.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ 329.09 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $19,907,000.00 | $5,706,000.00 |
| Revenue This Year | $21.40 | $13.73 |
| Revenue Next Year | $12.65 | $279.00 |
| P/E Ratio | $27.13 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.63 | $13.18 |
| 52 Week High | $41.97 | $34.29 |
Technical Indicators
Market Signals| Indicator | DCOM | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 67.07 |
| Support Level | $39.85 | $21.62 |
| Resistance Level | $41.45 | $34.18 |
| Average True Range (ATR) | 0.70 | 0.96 |
| MACD | -0.11 | 0.13 |
| Stochastic Oscillator | 42.86 | 80.37 |
Price Performance
Historical ComparisonAbout DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.